Register
FDA cautions about risk of neural tube birth defects with dolutegravir |
Journal Updates
eMediNexus Coverage from: 
FDA cautions about risk of neural tube birth defects with dolutegravir
eMediNexus,  20 May 2018
remove_red_eye 686 Views
#HIV AIDS #Infectious Diseases #Public Health

0 Read Comments                

In a drug safety communication, the US FDA has cautioned about the potential risk of neural tube birth defects with dolutegravir used to treat human immunodeficiency virus (HIV) in women, who received the drug at the time of becoming pregnant or early in the first trimester. The FDA has advised health care professional to get a pregnancy test before starting dolutegravir-containing and inform women of childbearing age about the potential risk of neural tube defects with this drug.
To continue reading this article
Sign in with Medtalks

Continue reading your article with a eMediNexus account.
Free Membership!